Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis

Table 1 Features of all trials included in the meta-analysis

Country	Year of RCT published	SCC or AC	Schedule of radiotherapy	Schedule of chemotherapy	Concurrent or sequential	Time of surgery
Norway	1992	SCC	35 Gy	Cisplatin: 20 mg/m2 D1-5, D15-19	Sequential	Not report
			1.75 Gy/d	Bleomycin: 10 mg/m2 D1-5, D15-19
			5 d/wk for 4 wk
Thailand	1994	SCC	40 Gy	Cisplatin: 100 mg/m2 D1, 29	Concurrent	4 wk after completion of chemotherapy
			2 Gy/d	FU: 1000 mg/m2 D1, D29-32
			5 d/wk for 4 wk
France	1994	SCC	20 Gy	Cisplatin: 100 mg/m2 D1,21	Sequential	D42
			2 Gy/d	FU: 600 mg/m2 D2-5, D22-25
			D8-19
Ireland	1996	AC	40 Gy	Cisplatin: 75 mg/m2 D7	Concurrent	8 wk after CRT
			2.67 Gy/ d	FU: 15 mg/kg D1-5
			D1-5, 8-12, 15-19	Week 1 and week 6
France	1997	SCC	37 Gy	Cisplatin: 80 mg/m2 D0-2	Sequential	2-4 wk after CRT
			3.7 Gy/d
			5 d/wk for 2 wk
USA	2001	SCC and AC	45 Gy	Cisplatin: 20 mg/m2 D1-5, 17-21	Concurrent	D42
			1.5 Gy bid	FU: 300 mg/m2 D1-21
			D1-5, 8-12, 15-19	Vinblastine: 1 mg/m2 D1-4, 17-20
China	2003	SCC	36 Gy	Cisplatin: 25 mg/m2 D2-5, D22-25	Sequential	3 wk after CRT
			3 Gy/d	FU: 1000 mg/m2 D1-5
			D21-24, 28-31, 35-38	500 mg/m2 D21-25
Korea	2004	SCC	45.6 Gy	Cisplatin: 60 mg/m2 D1, 21	Concurrent	3-4 wk after completion of radiotherapy
			1.2 Gy bid	FU: 1000 mg/m2 D2-5
			D1-28
Australia	2005	SCC and AC	35 Gy	Cisplatin: 80 mg/m2 D1	Concurrent	3-6 wk after completion of radiotherapy
			2.33 Gy/d	FU: 800 mg/m2 D2-5
			5 d/wk for 3 wk
Japan	2006	SCC	40 Gy	Cisplatin: 7 mg/m2	Concurrent	35-40 d after CRT
			2 Gy/d	FU: 350 mg/m2
			5 d/wk for 4 wk	5 d/wk for 4-6 wk
USA	2008	SCC and AC	50.4 Gy	Cisplatin: 100 mg/m2 D1,29	Concurrent	3-8 wk after CRT
			1.8 Gy/d	FU: 1000 mg/m2 D1-4, D29-32
			5 d/wk for 5.5 wk

SCC: Squamous cell carcinoma; AC: Adenocarcinoma; CRT: Chemoradiotherapy.